SWTX's market confidence has increased post-launch, with $40.2 million in product revenue and $19.5 million in collaboration revenue in the first quarter.Nirogacestat approval for desmoid tumors and ...
Source LinkSWTX's market confidence has increased post-launch, with $40.2 million in product revenue and $19.5 million in collaboration revenue in the first quarter.Nirogacestat approval for desmoid tumors and ...
Source Link
Comments